Clinical Trials
2 trialsNCT01270880 2018-09-18
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01368003 2015-09-01
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Dana-Farber Cancer Institute
Phase 2 Withdrawn